What do systematic reviews say?

74 questions · 74 findings · 20 reviews · Cystic Fibrosis and Genetic Disorders

Sort:Best matchNewest Highest certainty Download CSV

No studies found 29 · 39.2%GRADE not reported 0 · 0%Very low 11 · 14.9%Low 15 · 20.3%Moderate 15 · 20.3%High 4 · 5.4%

Hypertonic saline 3% to 7% vs Normal saline

Pulmonary exacerbations · adults and children with cystic fibrosis (during acute exacerbations of lung disease)

Hypertonic saline 3% to 7% showed no clear difference in pulmonary exacerbations compared with isotonic saline (low certainty).

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
HR 0.86 [0.57, 1.3]
1 study · 132 participants
Low

Hypertonic saline vs rhDNase with

Pulmonary exacerbations · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 47 participants
Very low

Hypertonic saline vs amiloride

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline vs sodium‐2‐mercaptoethane sulphonate (Mistabron®)

Pulmonary exacerbations · adults and children with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 29 participants
Very low

Hypertonic saline vs mannitol

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 7% vs xylitol

Pulmonary exacerbations · adults with cystic fibrosis

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
Low

Hypertonic saline 7% vs hypertonic saline

Pulmonary exacerbations · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Hypertonic saline 3% to 7% vs Normal saline

Pulmonary exacerbations · adults and children with cystic fibrosis (stable lung disease)

1 finding from 1 review

Nebulised hypertonic saline for cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 607 participants
Very low

Psychological interventions vs active comparators

Pulmonary exacerbations · adults (aged 16 years and over) with CF

1 finding from 1 review

Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 128 participants
Very low

Psychological interventions vs usual care

Pulmonary exacerbations · children, adolescents or adults with CF

1 finding from 1 review

Psychological interventions for improving adherence to inhaled therapies in people with cystic fibrosis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 607 participants
Moderate

Summary of findings: inhaled TOBI® (IV preparation) vs tobramycin

Pulmonary exacerbations · adults and children with cystic fibrosis and a positive microbiological isolate of P aeruginosa from a respiratory tract specimen

The review found no eligible studies for this question.

1 finding from 1 review

Inhaled anti‐pseudomonal antibiotics for long‐term therapy in cystic fibrosis 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: monoclonal antibody KB001‐A vs placebo

Pulmonary exacerbations · children (12 or over) and adults with cystic fibrosis and lung infection

Summary of findings: monoclonal antibody KB001‐A showed no clear difference in pulmonary exacerbations compared with placebo (low certainty).

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
RR 0.25 [0.03, 2.4]
2 studies · 196 participants
Low

Summary of findings: nitric oxide vs placebo

Pulmonary exacerbations · children (12 or over) and young adults with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: garlic supplementation vs placebo

Pulmonary exacerbations · children aged over eight and adults with cystic fibrosis and chronic pulmonary infection with P aeruginosa

The review found no eligible studies for this question.

1 finding from 1 review

Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ECM vs ECT

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ECM vs ECMM

Pulmonary exacerbations · children with cystic fibrosis and proven pancreatic insufficiency

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ECM vs a different ECM

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ECM vs TPE

Pulmonary exacerbations · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: ECM vs other enteric‐coated preparations

Pulmonary exacerbations · children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings: low‐dose vs high‐dose PERT

Pulmonary exacerbations · adults and children with cystic fibrosis

The review found no eligible studies for this question.

1 finding from 1 review

Pancreatic enzyme replacement therapy for people with cystic fibrosis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found